Newly Diagnosed Multiple Myeloma Clinical Trials in New York, New York
2 recruitingNew York, New York
Showing 1–2 of 2 trials
Recruiting
Phase 2
Horizon Two: HR NDMM (MMRC-100)
High Risk Newly Diagnosed Multiple Myeloma
Multiple Myeloma Research Consortium300 enrolled7 locationsNCT07053436
Recruiting
Phase 3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Multiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline520 enrolled181 locationsNCT06679101